This is further supported by studies showing that pharmacological inhibition of mitochondrial reactive oxygen species (ROS) (e.g., mitoTEMPO) or restoration of ATP via exogenous supplementation attenuates ERS markers (GRP78, CHOP) in PD models [41,44]. The gene discussed is DDIT3; the disease is Parkinson disease.